This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will pilot an innovative digital Contingency Management (CM) treatment delivered via mobile device to Medicaid beneficiaries with co-occurring opioid and alcohol use disorders. The $390,000 award, spanning from September 2024 to August 2027, aims to: 1) identify optimal approaches to engage Medicaid beneficiaries in digital CM through Medicaid claims data...
The National Institute on Drug Abuse (NIDA) awarded a $264,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Innovation Research And Training, Inc. (IRT), a woman-owned small business research organization based in Durham, North Carolina. The purpose of this 3-year project, beginning September 2024, is to evaluate the "Substance of Change: Building Assets in Mentees Affected by Substance Misuse" (SOC), an interactive, multimedia, web-based,...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $197,748 to The Regents of the University of California, San Francisco to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program. The goal is to improve treatment outcomes for individuals with opioid use disorder, particularly those using fentanyl, by overcoming barriers to successful buprenorphine initiation and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $722,876 to New York University School of Medicine to conduct a study characterizing complex opioid use disorder (OUD) care trajectories and outcomes following acute service utilization. The study aims to: 1) characterize real-world trajectories of OUD treatment in the year following hospital encounters among treatment-naive individuals and...
This $2,663,022 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a 5-year study to test the effectiveness, implementation, and cost of Cognitive Processing Therapy adapted for delivery in criminal justice settings (CPT-CJ) as an intervention to reduce post-incarceration drug use, mental health symptoms, and drug-related crime among justice-involved individuals with substance use disorders and trauma...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $348,756 to the University of Oklahoma Health Sciences Center to develop a mobile health (mHealth) intervention that provides psychosocial and self-management support to postpartum individuals recovering from opioid use disorder (OUD). The intervention, grounded in acceptance and commitment therapy (ACT) principles, will be iteratively developed...
This Project Grant award, with a total funding amount of $958,629, was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support the real-world adoption of an innovative digital health therapeutic called KIOS, which uses nonlinear control theory to track multiple symptoms (e.g., craving, mood, pain) and deliver personalized, evidence-based intervention strategies to patients with opioid use disorder...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), totaling $444,826, is focused on adapting and testing an innovative, trauma-informed intervention to reduce overdose risk among women re-entering the community from prison. The key activities include: 1) Adapting the Trust-Based Relational Intervention (TBRI) approach by engaging stakeholders to align it with the unique needs of justice-involved women,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to Mountainpass Technology LLC to develop, refine, and evaluate a customized version of their "MyTrials" integrated remote biomarker capture system for decentralized clinical trials (DCTs) focused on substance use disorders (SUDs). The project aims to address key methodological limitations of DCTs for SUDs by creating a product...
IMPLEMENTING A DIGITAL THERAPEUTIC TO ADDRESS SUBSTANCE USE DISORDERS AMONG PEOPLE WHO ARE INCARCERATED - PROJECT SUMMARY DESPITE THE HIGH PREVALENCE OF SUBSTANCE USE DISORDERS (SUDS), INCLUDING OPIOID USE DISORDER (OUD), AMONG PEOPLE INCARCERATED IN THE US, ONLY A SMALL PORTION RECEIVE SUD TREATMENT WHILE INCARCERATED. ONE BARRIER IS LIMITED EVIDENCE-BASED TREATMENT AVAILABILITY IN CORRECTIONAL FACILITIES. CONCERNING OUD, THOUGH A GROWING NUMBER OF FACILITIES ARE SCREENING FOR OUD AND PROVIDING MEDICATION FOR OUD (MOUD), SUPPORTING THESE SERVICES ACROSS CORRECTIONAL FACILITIES HAS BEEN LIMITED; ADJUNCTIVE BEHAVIORAL COUNSELING TO SUPPORT MOUD ADHERENCE AND OUTCOMES IS RECOMMENDED IN CLINICAL PRACTICE GUIDELINES, BUT AVAILABILITY MAY BE LIMITED IN CORRECTIONAL FACILITIES. FURTHERMORE, CORRECTIONAL MENTAL HEALTH STAFF REPORT HIGH BURNOUT, WHICH AFFECTS THE QUALITY OF CARE DELIVERED. DIGITAL THERAPEUTICS FOR SUDS-WHICH MAY OFFER AN ACCESSIBLE, LOW-COST, AND LOW- BURDEN OPTION FOR PROVIDING TREATMENT-WOULD BE HELPFUL IN CLOSING THE GAP BETWEEN INCARCERATED INDIVIDUALS WITH OUD AND OTHER SUD(S) WHO NEED TREATMENT AND SERVICES AVAILABLE IN CORRECTIONAL FACILITIES. THE PROPOSED TRAINING PLAN AND RESEARCH PROJECT OF THIS K23 APPLICATION WILL PROVIDE MENTORED TRAINING TO SUPPORT DR. JENNIFER LOYA'S PURSUIT OF AN INDEPENDENT RESEARCH CAREER CONDUCTING PATIENT-ORIENTED RESEARCH WITH DUAL EXPERTISE IN SUBSTANCE USE TREATMENT AND IMPLEMENTATION SCIENCE. THE TRAINING GOALS FOCUS ON GAINING KNOWLEDGE IN IMPLEMENTATION SCIENCE METHODS, LEARNING SPECIFIC QUALITATIVE METHODS AND RESPECTIVE DATA ANALYSIS, AND GAINING EXPERIENCING IN CONDUCTING A PILOT CLINICAL TRIAL, AS WELL AS ADVANCING CAREER DEVELOPMENT. COMPLEMENTING THESE GOALS, DR. LOYA WILL RECEIVE MENTORSHIP FROM EXPERTS IN THESE AREAS AND PARTICIPATE IN STRUCTURED DIDACTIC AND EXPERIENTIAL TRAINING THROUGH FORMAL COURSEWORK AND TRAININGS/WORKSHOPS, ATTENDANCE AT SEMINARS AND ANNUAL CONFERENCES, AND DIRECT RESEARCH ACTIVITIES. THE RESEARCH PLAN AIMS TO GAIN A COMPREHENSIVE UNDERSTANDING OF HOW AN EVIDENCE-BASED DIGITAL THERAPEUTIC OF COGNITIVE AND BEHAVIORAL SKILLS FOR SUBSTANCE USE-COMPUTER BASED TRAINING FOR COGNITIVE BEHAVIORAL THERAPY (CBT4CBT)-COULD BE EFFECTIVELY IMPLEMENTED AS A TREATMENT FOR INCARCERATED PEOPLE WITH CURRENT OUD/SUD. IN AIM 1, ATTITUDES AND PERCEPTIONS OF USING A DIGITAL THERAPEUTIC FOR SUDS AND INPUT REGARDING BARRIERS TO AND FACILITATORS FOR IMPLEMENTING CBT4CBT WILL BE ASSESSED WITH QUALITATIVE INDIVIDUAL INTERVIEWS AMONG ADDICTION TREATMENT PROVIDERS IN TWO CONNECTICUT CORRECTIONAL FACILITIES. IN AIM 2, WITH IMPLEMENTATION RECOMMENDATIONS FROM PROVIDERS INCORPORATED, CBT4CBT WILL BE IMPLEMENTED THROUGH A PILOT CLINICAL TRIAL AMONG 50 INCARCERATED INDIVIDUALS WITH CURRENT OUD (PRIMARY), AS WELL AS OTHER SUD(S), TO EXAMINE ITS FEASIBILITY AND ACCEPTABILITY, AS WELL AS PRELIMINARY EFFICACY. RESULTS OF THIS PROJECT WILL INFORM FUTURE EFFORTS TO MODIFY AND ADAPT CBT4CBT TO ENHANCE IMPLEMENTATION AND EXAMINE ITS EFFICACY AS A PRE-RELEASE INTERVENTION TO IMPROVE SUBSTANCE USE OUTCOMES POST-RELEASE. COMPLETION OF THE PROPOSED TRAINING PLAN AND RESEARCH PROJECT WILL OPTIMALLY POSITION DR. LOYA TO PURSUE A CAREER AS AN INDEPENDENT PATIENT-ORIENTED RESEARCHER.